Newark, New Castle, USA, July 05, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the global human microbiome market was valued at US$ 74.21 billion and is expected to rise at a revenue CAGR of 25.0% to reach US$ 552.92 billion by 2031.
The global market for human microbiomes was analyzed, and it is expected to rise significantly during the forecast period. The collection of all microbiotas found on or in human tissues, biofluids, and anatomical locations is known as the human microbiome.
Recent Development in the Global Human Microbiome Market:
- In September 2022, Ferring Pharmaceuticals' RBX2660 exploratory microbiota-based live biotherapeutic research received FDA Vaccines and Related Biological Products Advisory Committee approval for its ability to lower the recurrence of C. difficile infection (CDI) following antibiotic therapy.
Download the Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/human-microbiome-market/7940
Human Microbiome Market Scope
| Report Attribute | Details |
| Market Size Value in 2022 | US$ 74.21 billion |
| Revenue Forecast in 2031 | US$ 552.92 billion |
| Growth Rate | CAGR of 25.0% from 2023-2031 |
| Base Year for Estimation | 2022 |
| Forecast Period | 2022-2030 |
| Historical Year | 2021 |
| Segments Covered | Product, Disease, Application, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Key Takeaways:
- The rising prevalence of chronic diseases and infections related to microbials is driving the market revenue share.
- The rising demand for personalized medicines is boosting market revenue growth.
- Several advancements in microbial technology are creating a strong product pipeline.
Market Drivers and Restraints:
The driving factor for the human microbiome market revenue is the increasing elderly population and burden of illnesses linked to lifestyle. Furthermore, high impact rendering factors that are expected to promote market expansion include expanding funding efforts and government programs to encourage this research, contributing to the market revenue growth.
However, increased regulatory oversight of drugs based on the microbiome is expected to restrain market revenue growth.
Market Segmentation:
Segmentation By Product
Based on products, the global human microbiome market is segmented into probiotics, prebiotics, drugs, medical food, and others. Due to a growing interest among consumers in preventative healthcare and the identification of efficient probiotic strains, the probiotics segment accounts for the largest market revenue share.
Segmentation By Disease
Based on the disease, the global human microbiome market is segmented into obesity and diabetes, autoimmune disorders, cancer, gastrointestinal disorders, endocrine & disorders, and others. The obesity segment accounts for the largest revenue share, followed by diabetes and cancer.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/human-microbiome-market/7940
Segmentation By Application
Based on application, the global human microbiome market is segmented into therapeutics and diagnostics. Due to the wide utilization during the Covid-19 pandemic, the microbiome therapeutics segment accounts for a significant revenue share in the global market for human microbiome.
Regional Growth Dynamics
Based on the region, the global human microbiome market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. Due to a sophisticated healthcare system, a rising geriatric population, and an increase in the prevalence of chronic disease, North America accounts for the most significant revenue share in the global market.
Competitive Landscape
The top market players operating in the global market for human microbiome are as follows:
- Microbiome Therapeutics LLC
- Osel, Inc.
- Rebiotix, Inc.
- Enterome Biosciences SA
- 4D Pharma
- Metabiomics Corp. (BioSpherex LLC)
Report Coverage
Growth Plus Reports studied the global human microbiome market in-depth and analyzed the market characteristics, potential investment areas, analytics of regional growth, revenue forecast, competitive market players, mergers, and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years - 2021
- Base Years - 2022
- Forecasted Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- Epidemiology Data of Top Indications
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL HUMAN MICROBIOME MARKET - ANALYSIS & FORECAST, BY PRODUCT
- Probiotics
- Prebiotics
- Drugs
- Medical Food
- Others
- GLOBAL HUMAN MICROBIOME MARKET - ANALYSIS & FORECAST, BY DISEASE
- Obesity & Diabetes
- Autoimmune Disorders
- Cancer
- Gastrointestinal Disorders
- Endocrine Disorders
- Others
- GLOBAL HUMAN MICROBIOME MARKET - ANALYSIS & FORECAST, BY APPLICATION
- Therapeutics
- Diagnostics
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-7940
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Acute Flaccid Myelitis Market by Treatment Type (Pharmacological Treatment, Physical & Occupational Therapy, Plasmapheresis, and Others) - Global Outlook & Forecast 2023-2031
Subcutaneous Immunoglobulin (SCIg) Therapy Market by Indication (Primary Immunodeficiency Disease, Chronic Inflammatory Demyelinating Polyneuropathy), Distribution Channel (Hospital Pharmacies, Online Pharmacies) – Global Outlook & Forecast 2023-2031
Hydatid Disease Treatment Market by Drug (Mebendazole, Albendazole), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
High-Grade Neuroendocrine Neoplasms Market by Drug Class (Platinum Coordination Complexes, Somatostatin Analogues), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Postoperative Pain Medication Market by Drug Class (NSAIDS, Opioids), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Unleashing the Power of Innovation in Med Tech: https://growthplusmedtechroundup.com
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".
